Uncontrolled Asthma Improved With Tezepelumab

subcutaneous injection, vaccination
subcutaneous injection, vaccination
Tezepelumab improved asthma control in patients with severe or uncontrolled asthma.

This article is part of Pulmonology Advisor‘s coverage of the American Academy of Allergy, Asthma & Immunology, taking place in Orlando, Florida. Our staff will report on medical research related to asthma and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI/WAO 2018.

ORLANDO — In a phase 2b clinical trial, tezepelumab improved asthma control in patients with uncontrolled asthma, according to data presented at the 2018 Joint Congress of the American Academy of Allergy, Asthma & Immunology and World Allergy Organization (AAAAI/WAO), held March 2-5, 2018, in Orlando, Florida.

Jonathan Corren, MD, from the Allergy Medical Clinic in Los Angeles, California, and colleagues conducted a randomized, double-blind study (ClinicalTrials.gov Identifier: NCT02054130) for 52 weeks involving patients with serious, uncontrolled asthma to assess the outcomes of tezepelumab treatment.

Participants were treated with either subcutaneous tezepelumab once every 2 weeks or placebo. Of the 584 total volunteers, those who were given tezepelumab received a low dose (70 mg once every 4 weeks), medium dose (210 mg once every 4 weeks), or high dose (280 mg once every 2 weeks).

At the end of the study, the authors reported average asthma control for placebo (−0.89), tezepelumab low dose (−1.13), tezepelumab medium dose (−1.16), and tezepelumab high dose (−1.22) compared with baseline results. A higher proportion of patients in the tezepelumab groups had either well-controlled (27.2% in tezepelumab overall vs 14.9% in placebo) or partially controlled (22.0% in tezepelumab overall vs 19.1% in placebo) asthma at 52 weeks.

Median duration from application to well-controlled or partially controlled asthma decreased by half for the control group compared with the placebo group (70 days in tezepelumab overall vs 140 days in placebo; P <.05).

Related Articles

Visit Pulmonology Advisor‘s conference section for continuous coverage from AAAAI/WAO 2018


Corren J, Parnes JR, Wang L, et al. Tezepelumab demonstrates clinically meaningful improvements in asthma control (ACQ-6) in patients with uncontrolled asthma: results from a phase 2b clinical trial Presented at the American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress; March 2-5, 2018; Orlando, FL. Abstract 257.